The Conversation (0)
Akorn (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Bimatoprost Ophthalmic Solution, 0.03%. As quoted in the press release: The product is manufactured at Akorn’s Amityville, New York manufacturing facility. According to IQVIA, …
Akorn (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Bimatoprost Ophthalmic Solution, 0.03%.
As quoted in the press release:
The product is manufactured at Akorn’s Amityville, New York manufacturing facility.
According to IQVIA, sales of bimatoprost ophthalmic solution, 0.03% were approximately $63.5 million for the twelve months ended August 2018.
Bimatoprost ophthalmic solution, 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.